There is good reason to be optimistic about eliminating HIV/AIDS, says an editorial in New Scientist.
《新科學家》的一篇社論說，
有很好的理由對根除愛滋病保持樂觀。
The strongest hope lies in a potential "cure" based on gene therapy, it says. US company Sangamo Biosciences is developing a gene therapy to emulate the effect of a bone marrow transplant that "vanquished" the virus in an HIV patient. If it works, patients could be cured with a single shot of gene therapy instead of a lifetime of antiretroviral therapy (ART), says the editorial.
它說最大的希望在於一種可能的“治癒”愛滋病的基因療法。 美國的Sangamo生物科學公司正在開發一種模仿骨髓移植效應的基因療法， 從而“擊敗”愛滋病病毒感染者體內的病毒。 該社論說， 如果它是可行的， 患者不需要終身接受抗逆轉錄病毒治療（ART）， 而只需接受一針的基因治療就可痊癒。
And ARTs are themselves a reason for optimism, it adds. According to the WHO, existing ARTs could eliminate HIV in Africa by 2050 — if accompanied by regular testing and quick treatments. Such a long-term programme would be expensive but at US$85 billion, the cost is a fraction of the US$700 billion recently spent to bail out US banks.
它還說， 而ARTs本身也是讓人感到樂觀的理由。 根據世界衛生組織， 到2050年， 現有的ARTs可以在非洲消滅愛滋病——如果伴隨著定期測試和快速治療的話。 這種長期專案是昂貴的，
And ART prices could fall. GlaxoSmithKline has said it will offer poor countries all its medicines at 25 per cent less than the typical price in the developed world.
而ART的價格可能下降。 葛蘭素史克公司說它將為窮國以發達國家典型藥價25%以下的價格提供其所有藥物。
With enough time and money, the editorial concludes we can finally start to rid the world of HIV/AIDS.
這篇社論得出結論說， 有了足夠的時間和金錢， 我們終於可以開始讓全世界擺脫愛滋病。
